Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors

The rest is here:
Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology

Continued here:
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer 

TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid’s elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers.

Read the rest here:
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

February 10, 2025

Read more:
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025

See the rest here:
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) joint congress.

More here:
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology /...

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial

Read more:
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Data presented at the 2025 Crohn’s and Colitis Congress

Visit link:
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced an upcoming poster for bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in San Diego, CA, February 28-March 3, 2025.

Follow this link:
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to participate in the following upcoming investor conferences.

Read the original here:
Capricor Therapeutics to Participate in Upcoming Investor Conferences

Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025

Read more:
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

LOS ANGELES,CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and select immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis. As of June 2024 public information, FDA approved less than half of RMAT applications submitted to the agency during the last eight years. FDA RMAT designation requires that a drug is an advanced regenerative medicine, targets a serious condition, with the potential to treat, modify, reverse, or cure, and preliminary clinical evidence has indicated that the drug has the potential to address these unmet medical needs.

Read the rest here:
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory...

Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported certain preliminary unaudited financial results for the full year ended December 31, 2024, including cash, cash equivalents, and revenues, and also provided a business update.

Continued here:
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present two posters on its lead candidate, ‘1104, at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress to be held February 28-March 3, 2025 in San Diego, CA.

Read the original post:
Revolo to Present at the 2025 AAAAI / WAO Joint Congress

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million

More here:
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET.

Read more from the original source:
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the “SEC”) of the Company’s Registration Statement on Form S-1 (No. 333-282781), as amended, originally filed on October 23, 2024 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

More here:
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

WARREN, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.

View post:
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities, in exchange for a total cash consideration of EUR 1.5 billion. After more than 25 years of successful collaboration, a strategic repositioning at dsm-firmenich allowed this opportunity to materialize. This acquisition is aligned with Novonesis’ growth strategy and expands its presence across the animal biosolutions value chain. Financially, this transaction is accretive to revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies.

Go here to see the original:
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance

Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis’ growth strategy and therapeutic area focus, leveraging the company’s strength and expertise in the cardiovascular area.

See more here:
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront